Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
"Oh, oh, oh, Ozempic." Those are the upbeat lyrics from the song in the TV commercials for Ozempic, which are based on the 1974 hit song "Magic," recorded by Pilot. However, the lyrics might now have a different connotation -- one that isn't so magical and upbeat for Ozempic's maker, Novo Nordisk (NYSE: NVO).
Ozempic has become a sensation (along with its sibling product, Wegovy), thanks largely to its remarkable effectiveness in helping people lose weight. Last week, though, Truveta Research released an analysis that could be very bad news for the popular drug and Novo Nordisk.
On Nov. 22, 2023, Truveta researchers published data from a real-world evidence study comparing semaglutide and tirzepatide on the medRxiv (pronounced "med-archive") pre-print website. Novo Nordisk markets semaglutide under the Ozempic brand for treating type 2 diabetes and under the Wegovy brand for weight loss.
Source Fool.com
